Sciele Pharma (MM) (NASDAQ:SCRX)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sciele Pharma (MM) Charts. Click Here for more Sciele Pharma (MM) Charts.](/p.php?pid=staticchart&s=N%5ESCRX&p=8&t=15)
On October 9, 2008, Shionogi & Co., Ltd. (“Shionogi”)
and Sciele Pharma, Inc. (“Sciele”)
(NASDAQ: SCRX) announced the successful completion of the cash tender
offer by Shionogi’s indirect wholly owned
subsidiary, Tall Bridge, Inc. (“Purchaser”),
to acquire all outstanding shares of common stock of Sciele for $31.00
per share. The subsequent offering period for the tender offer expired
at 5:00 p.m., New York City time, on Wednesday, October 8, 2008. The
depositary for the tender offer has advised Shionogi that, as of the
expiration of the subsequent offering period, a total of approximately
29,758,788 shares were validly tendered in the offering period,
representing approximately 92.0% of all outstanding shares of Sciele.
Purchaser has accepted for payment all shares that were validly tendered
and not withdrawn during the offering period, and payment for such
shares has or will be made promptly, in accordance with the terms of the
tender offer.
Shionogi intends to complete the acquisition of Sciele through a
short-form merger pursuant to the Delaware General Corporation Law
effective as of 5:00 p.m. Eastern Daylight Time on October 9, 2008,
without a vote or meeting of Sciele’s
stockholders, after which Sciele will become an indirect wholly owned
subsidiary of Shionogi. In the merger, each outstanding share (other
than any shares in respect of which appraisal rights are validly
exercised under Delaware law and any shares owned by Sciele, Shionogi or
any of their subsidiaries) will be converted into the right to receive
the same $31.00 in cash per share, without interest, that was paid in
the tender offer. Following the merger, Sciele’s
common stock will cease to be traded on the NASDAQ Global Select Market.
About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a major research-driven Japanese pharmaceutical
manufacturer. The company’s primary
businesses are research and development, manufacturing, marketing, and
import and export sales of pharmaceuticals and diagnostics. Shionogi
follows a basic policy of continually providing the superior medicines
essential to people’s health. For more
details, please visit www.shionogi.co.jp
About Sciele Pharma, Inc.
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales,
marketing and development of branded prescription products focused on
the therapeutic areas of Cardiovascular, Diabetes, Women's Health and
Pediatrics. The Company's Cardiovascular and Diabetes products treat
patients with high cholesterol, hypertension, high triglycerides,
unstable angina and Type 2 diabetes; its Women's Health products are
designed to improve the health and well-being of women and mothers and
their babies; and its Pediatrics products treat allergies, asthma,
coughs and colds, and attention deficit and hyperactivity disorder
(ADHD). The Company was founded in 1992 and is headquartered in Atlanta,
Georgia. The Company employs more than 1,000 people. The Company's
success is based on placing the needs of patients first, improving
health and quality of life, and implementing its business platform –
an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity,
and Teamwork. For more information on Sciele, please visit www.sciele.com.